Skip to main content
Premium Trial:

Request an Annual Quote

DNA Sciences Announces Management Changes

NEW YORK, Feb 7 – Population genetics company DNA Sciences said Wednesday that its chief operating officer and head of technology development, Greg Went, resigned.

The Fremont, Calif.-based company said it would not replace Went, who left to “pursue other interests.”

DNA Sciences also announced that it appointed Christopher Burrow to head the company’s clinical research efforts. He will be involved with the company's genetic research and product development programs. He will also work with outside scientific collaborators and medical groups.

Burrow will report to Raymond White, DNA Sciences' chief scientific officer.

DNA Sciences, which recently filed for an IPO, studies the role genes play in diseases such as cancer, asthma, and diabetes. It is also planning to commercialize diagnostic tests.  

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.